EGFR inhibitor gefitinib prevents progression of pancreatic lesions to carcinoma in a conditional LSL-Kras(G12D/+) transgenic mice model

Podobne zapisy

• Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48(Cre/+).LSL-Kras(G12D/+) mice
  od: Mohammed, Altaf, i wsp.
  Wydane: (2012)
• Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma
  od: Rao, Chinthalapally V., i wsp.
  Wydane: (2015)
• Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48(Cre/+)-LSL-Kras(G12D/+) Mice
  od: Rao, Chinthalapally V, i wsp.
  Wydane: (2012)
• Endogenous n-3 Polyunsaturated Fatty Acids Delay Progression of Pancreatic Ductal Adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) Mice
  od: Mohammed, Altaf, i wsp.
  Wydane: (2012)
• Loss of natural killer T cells promotes pancreatic cancer in LSL‐Kras(G12D/+) mice
  od: Janakiram, Naveena B., i wsp.
  Wydane: (2017)